Shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) have earned an average rating of “Hold” from the seven analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised RECKITT BENCKIS/S from a “sell” rating to a “hold” rating in a report on Saturday, June 9th. Credit Suisse Group reaffirmed an “underperform” rating on shares of RECKITT BENCKIS/S in a report on Friday, May 4th. Deutsche Bank reaffirmed a “buy” rating on shares of RECKITT BENCKIS/S in a report on Tuesday, April 3rd. Finally, Societe Generale raised RECKITT BENCKIS/S from a “hold” rating to a “buy” rating in a report on Thursday, March 22nd.
Shares of RECKITT BENCKIS/S traded down $0.12, hitting $16.88, on Wednesday, Marketbeat reports. The company had a trading volume of 184,118 shares, compared to its average volume of 886,153. The company has a market cap of $59.76 billion, a PE ratio of 24.11, a price-to-earnings-growth ratio of 4.34 and a beta of 0.97. RECKITT BENCKIS/S has a 1 year low of $15.14 and a 1 year high of $21.79. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.85.
RECKITT BENCKIS/S Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amop茅, and Strepsils brand names.
No comments:
Post a Comment